DMD and Duchenne muscular dystrophy: Amongst ongoing DMD clinical trials with innovative medicines, some are based on exon-skipping antisense oligonucleotides (ASO) technology, and at least three are investigating the approach of systemic gene therapy using a micro-dystrophin gene, and in one of them, the age eligible for the study starts at 3 months of age [4].